This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Nicotine replacement therapy

Authoring team

  • there is evidence that NRT doubles the smoking cessation rate compared with placebo
  • NRT is less addictive than smoking
  • NRT, unlike tobacco smoking, does not provide tar products and carbon monoxide
  • currently, there is no evidence that nicotine causes cancer
  • NRT provides nicotine in a slower and less satisfying way than tobacco smoking BUT is safer and much less addictive
  • nicotine does have vascular effects and product licences require caution in patients with established vascular disease, especially after a recent event. However continuance of tobacco smoking doubles risk of recurrent events and mortality
  • nicotine may cause nausea, dizziness, palpitations and headaches in patients who have not become tolerant to it
  • NRT is not a magic cure but helps with withdrawal and craving symptoms
  • use in pregnancy - see linked item
  • the majority of NRT studies fail to follow up patients for more than a year. Therefore it is difficult to assess if health improvements achieved by NRT use are maintained long term
  • a systematic review (4) regarding the use of NRT concluded:
    • all of the commercially available forms of NRT (gum, transdermal patch, nasal spray, inhaler and sublingual tablets/lozenges) are effective as part of a strategy to promote smoking cessation
    • NRT increases the odds of quitting approximately 1.5 to 2 fold regardless of setting
    • effectiveness of NRT appears to be largely independent of the intensity of additional support provided to the smoker -provision of more intense levels of support, although beneficial in facilitating the likelihood of quitting, is not essential to the success of NRT

Notes:

  • GPs have been able to prescribe nicotine replacement therapy products from 17 April 2001
  • a systematic review of various pharmacotherapies for smoking cessation concluded that (2):
    • varenicline, bupropion and the 5 nicotine replacement therapies were all more efficacious than placebo at promoting smoking abstinence at 6 and 12 months

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.